

Charles E Inturrisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2821377/publications.pdf>

Version: 2024-02-01

44
papers

3,125
citations

279701

23
h-index

276775

41
g-index

44
all docs

44
docs citations

44
times ranked

2072
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacology of Opioids for Pain. <i>Clinical Journal of Pain</i> , 2002, 18, S3-S13.	0.8	498
2	Central nervous system excitatory effects of meperidine in cancer patients. <i>Annals of Neurology</i> , 1983, 13, 180-185.	2.8	416
3	Sublingual absorption of selected opioid analgesics. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 335-342.	2.3	245
4	Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 392-401.	2.3	233
5	Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society. <i>Journal of Pain</i> , 2014, 15, 321-337.	0.7	203
6	The levels of methadone in the plasma in methadone maintenance. <i>Clinical Pharmacology and Therapeutics</i> , 1972, 13, 633-637.	2.3	133
7	The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 422-431.	2.3	126
8	Disposition of methadone in man after a single oral dose. <i>Clinical Pharmacology and Therapeutics</i> , 1972, 13, 923-930.	2.3	125
9	N-Methyl-D-Aspartate (NMDA) Receptors, Mu and Kappa Opioid Tolerance, and Perspectives on New Analgesic Drug Development. <i>Neuropsychopharmacology</i> , 1995, 13, 347-356.	2.8	109
10	Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 565-577.	2.3	104
11	Personalized Medicine and Opioid Analgesic Prescribing for Chronic Pain: Opportunities and Challenges. <i>Journal of Pain</i> , 2013, 14, 103-113.	0.7	98
12	Improving the Pharmacologic Management of Pain in Older Adults: Identifying the Research Gaps and Methods to Address Them. <i>Pain Medicine</i> , 2011, 12, 1336-1357.	0.9	93
13	Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 631-641.	2.3	90
14	Estradiol and progesterone differentially regulate formalin-induced nociception in ovariectomized female rats. <i>Hormones and Behavior</i> , 2006, 49, 441-449.	1.0	79
15	Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 157-167.	2.3	61
16	Stabilization of the μ -Opioid Receptor by Truncated Single Transmembrane Splice Variants through a Chaperone-like Action. <i>Journal of Biological Chemistry</i> , 2013, 288, 21211-21227.	1.6	51
17	Disposition of propoxyphene and norpropoxyphene in man after a single oral dose. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 15, 302-309.	2.3	45
18	NMDA antagonists and clonidine block c-fos expression during morphine withdrawal. <i>Synapse</i> , 1995, 20, 68-74.	0.6	43

#	ARTICLE	IF	CITATIONS
19	Antisense Oligodeoxynucleotides to the Cloned δ Receptor DOR δ 1: Uptake, Stability, and Regulation of Gene Expression. <i>Journal of Neurochemistry</i> , 1995, 65, 1981-1987.	2.1	37
20	DISPOSITION OF NARCOTICS AND NARCOTIC ANTAGONISTS. <i>Annals of the New York Academy of Sciences</i> , 1976, 281, 273-287.	1.8	33
21	δ -ENDORPHIN IMMUNOREACTIVITY IN THE PLASMA OF PSYCHIATRIC PATIENTS RECEIVING ELECTROCONVULSIVE TREATMENT. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 413-423.	1.8	32
22	Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala ² -D-Leu ⁵ -enkephalin. <i>Annals of Neurology</i> , 1986, 20, 218-222.	2.8	25
23	Acute and Persistent Suppression of Preproenkephalin mRNA Expression in the Striatum Following Developmental Hypoxic-Ischemic Injury. <i>Journal of Neurochemistry</i> , 1994, 62, 1878-1886.	2.1	25
24	Effects of acetylmethadol on plasma testosterone. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 371-374.	2.3	24
25	Characterization of the Safety and Pharmacokinetic Profile of d-Methadone, a Novel N-Methyl-d-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 226-237.	0.7	24
26	Retinoic acid-induced increase in delta-opioid receptor and N-Methyl-d-Aspartate receptor mRNA levels in neuroblastoma A— glioma (NG108-15) cells. <i>Brain Research Bulletin</i> , 1996, 39, 193-199.	1.4	22
27	Retinoic acid regulation of mu opioid receptor and c-fos mRNAs and AP-1 DNA binding in SH-SY5Y neuroblastoma cells. <i>Molecular Brain Research</i> , 2002, 99, 34-39.	2.5	21
28	Pain Assessment, Management, and Control Among Patients 65 Years or Older Receiving Hospice Care in the U.S.. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 663-672.	0.6	20
29	Patient-Reported Outcomes and Opioid Use by Outpatient Cancer Patients. <i>Journal of Pain</i> , 2018, 19, 278-290.	0.7	18
30	The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 196-201.	1.3	18
31	Metrazole induction of c-fos and proenkephalin gene expression in the rat adrenal and hippocampus: pharmacological characterization. <i>Molecular Brain Research</i> , 1993, 20, 118-124.	2.5	15
32	Dynorphin A(1-13) Analgesia in Opioid-Treated Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 1999, 17, 33-42.	1.1	10
33	Section Review Central & Peripheral Nervous Systems: Pharmacological Modulation of Opioid Tolerance. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 271-281.	1.9	8
34	Patient-Reported Outcomes and Opioid Use in Outpatients With Chronic Pain. <i>Journal of Pain</i> , 2017, 18, 583-596.	0.7	7
35	The effect of obesity on pain severity and pain interference. <i>Pain Management</i> , 2021, 11, 571-581.	0.7	7
36	Using Chronic Pain Outcomes Data to Improve Outcomes. <i>Anesthesiology Clinics</i> , 2016, 34, 395-408.	0.6	6

#	ARTICLE	IF	CITATIONS
37	The Tri-Institutional Pain Registry—Analysis of Outpatient Pain Management at a Specialized Cancer Center. <i>Pain Medicine</i> , 2017, 18, 2474-2484.	0.9	6
38	Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy. <i>Journal of Opioid Management</i> , 2020, 16, 111-118.	0.2	5
39	Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl. <i>Cancer Medicine</i> , 2019, 8, 7516-7522.	1.3	4
40	Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers. <i>American Journal on Addictions</i> , 1993, 2, 34-38.	1.3	4
41	Naltrexone Maintenance. <i>American Journal on Addictions</i> , 1993, 2, 34-38.	1.3	1
42	Pharmacology of analgesia: basic principles. , 2003, , 111-123.		1
43	Consensus guideline on parental methadone use in pain and palliative care. <i>Palliative and Supportive Care</i> , 2008, 6, 321-321.	0.6	0
44	Understanding Opioid Actions, Pain and Analgesia: A Tribute to Dr. Gavril Pasternak. <i>Cellular and Molecular Neurobiology</i> , 2021, 41, 827-834.	1.7	0